Total raised
$2.5M
Last: Seed 2021-11
Stage
Seed
Founded
2021
Headcount
4
HQ
Be'er Sheva
Sector
Health Tech & Life Sciences
About
Neuromagen Pharma is a pharmaceutical company developing a new class of innovative small molecules that activate telomerase reverse transcriptase (TERT), an enzyme that plays a major role in preventing cellular senescence.
The companys mission is to develop drugs to delay the onset and the progression of neurodegenerative diseases such as ALS and to improve and extend patients lives.
Neuromagen Pharma received FDA Orphan Drug Designation for its AGS-499 Drug Candidate to Slow the Progression of ALS (Amyotrophic Lateral Sclerosis).
Funding history · 1 round · $2.5M total
2021-11
Seed
$2.0M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was Neuromagen Pharma founded?
- Neuromagen Pharma was founded in May 2021.
- What is Neuromagen Pharma's primary focus?
- Neuromagen Pharma is a pharmaceutical company developing innovative small molecules to activate telomerase reverse transcriptase (TERT) for neurodegenerative diseases like ALS.
- Has Neuromagen Pharma received any significant drug designations?
- In May 2022, Neuromagen Pharma received FDA Orphan Drug Designation for its AGS-499 drug candidate, intended to slow the progression of ALS.
- What was Neuromagen Pharma's last funding round?
- Neuromagen Pharma completed a Seed funding round in November 2021, raising $2,000,000.
- Did Neuromagen Pharma receive any grants?
- In March 2022, Neuromagen Pharma received a grant of $500,000 from the IIA (Israel Innovation Authority).
- How many employees does Neuromagen Pharma currently have?
- Neuromagen Pharma currently has 4 employees.
- Who are the founders of Neuromagen Pharma?
- The founders of Neuromagen Pharma are Gil Ben-Menachem and Esther Priel.
- What was a recent appointment to Neuromagen Pharma's Scientific Advisory Board?
- In June 2022, Neuromagen Pharma announced the appointment of Professor Gal Ifergane, Head of the Neurology Department at Soroka Medical Center, to its Scientific Advisory Board.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCellsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
pharmaceuticalsamyotrophic-lateral-sclerosis-alsdegenerative-diseasesdrug-developmentcells